MET and melanoma: Another combination of afatinib with crizotinib (a MET inhibitor) showed efficacy, was proposed as a promising alternative targeted therapy option for melanoma irrespective of BRAF/NRAS mutational status, and may overcome resistance to BRAF inhibitors (Table 6) [123].